Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Zorn

Showing results (31-40 of 75) with videos related to

Pageof 8
Sort By:
Lung|January 1, 1978
Sarcoidosis and mononuclear phagocytesJ B Gee, P T Bodel, S K Zorn, et al.
Hereditary Cancer in Clinical Practice|May 23, 2022
Statewide trends and factors associated with genetic testing for hereditary cancer risk in Arkansas 2013-2018Mahip Acharya, Kristin K Zorn, Melinda E Simonson, et al.
Familial Cancer|May 31, 2012
A multidisciplinary clinic for individualizing management of patients at increased risk for breast and gynecologic cancerNatalie J Engel, Patricia Gordon, Darcy L Thull, et al.
Gynecologic Oncology|April 29, 2014
Oxaliplatin salvage for recurrent ovarian cancer: a single institution's experience in patient populations with platinum resistant disease or a history of platinum hypersensitivitySarah E Taylor, Tiffany L Beck, Thomas C Krivak, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 28, 2011
Possible use of CA-125 level normalization after the third chemotherapy cycle in deciding on chemotherapy regimen in patients with epithelial ovarian cancer: brief reportMalgorzata E Skaznik-Wikiel, Paniti Sukumvanich, Sushil Beriwal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2003
Choice of normal ovarian control influences determination of differentially expressed genes in ovarian cancer expression profiling studiesKristin K Zorn, Amir A Jazaeri, Christopher S Awtrey, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 7, 2016
Second-line Intraperitoneal Platinum-based Therapy Leads to an Increase in Second-line Progression-free Survival for Epithelial Ovarian CancerMichelle M Boisen, Jamie L Lesnock, Scott D Richard, et al.
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education|April 6, 2021
What's in Between the Lines: Assessing the Readability, Understandability, and Actionability in Breast Cancer Survivorship Print MaterialsPearman D Parker, Arpan V Prabhu, L Joseph Su, et al.
Gynecologic Oncology|May 6, 2008
Preoperative intensity-modulated radiotherapy and chemotherapy for locally advanced vulvar carcinomaSushil Beriwal, Devin Coon, Dwight E Heron, et al.
Acta Cytologica|August 1, 2012
Heavy cervical cancer burden in elderly women: how can we improve the situation?Malgorzata E Skaznik-Wikiel, Paniti Sukumvanich, R Marshall Austin, et al.
Pageof 8

Showing results (31-40 of 75) with videos related to

Sort By:
Pageof 8
Lung|January 1, 1978
Sarcoidosis and mononuclear phagocytesJ B Gee, P T Bodel, S K Zorn, et al.
Hereditary Cancer in Clinical Practice|May 23, 2022
Statewide trends and factors associated with genetic testing for hereditary cancer risk in Arkansas 2013-2018Mahip Acharya, Kristin K Zorn, Melinda E Simonson, et al.
Familial Cancer|May 31, 2012
A multidisciplinary clinic for individualizing management of patients at increased risk for breast and gynecologic cancerNatalie J Engel, Patricia Gordon, Darcy L Thull, et al.
Gynecologic Oncology|April 29, 2014
Oxaliplatin salvage for recurrent ovarian cancer: a single institution's experience in patient populations with platinum resistant disease or a history of platinum hypersensitivitySarah E Taylor, Tiffany L Beck, Thomas C Krivak, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 28, 2011
Possible use of CA-125 level normalization after the third chemotherapy cycle in deciding on chemotherapy regimen in patients with epithelial ovarian cancer: brief reportMalgorzata E Skaznik-Wikiel, Paniti Sukumvanich, Sushil Beriwal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2003
Choice of normal ovarian control influences determination of differentially expressed genes in ovarian cancer expression profiling studiesKristin K Zorn, Amir A Jazaeri, Christopher S Awtrey, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 7, 2016
Second-line Intraperitoneal Platinum-based Therapy Leads to an Increase in Second-line Progression-free Survival for Epithelial Ovarian CancerMichelle M Boisen, Jamie L Lesnock, Scott D Richard, et al.
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education|April 6, 2021
What's in Between the Lines: Assessing the Readability, Understandability, and Actionability in Breast Cancer Survivorship Print MaterialsPearman D Parker, Arpan V Prabhu, L Joseph Su, et al.
Gynecologic Oncology|May 6, 2008
Preoperative intensity-modulated radiotherapy and chemotherapy for locally advanced vulvar carcinomaSushil Beriwal, Devin Coon, Dwight E Heron, et al.
Acta Cytologica|August 1, 2012
Heavy cervical cancer burden in elderly women: how can we improve the situation?Malgorzata E Skaznik-Wikiel, Paniti Sukumvanich, R Marshall Austin, et al.
Pageof 8